Shared on27 Aug 25Fair value Increased 4.20%
Beam Therapeutics’ consensus price target has increased to $45.92, reflecting notable improvements in net profit margin and a lower future P/E, signaling enhanced profitability and a more attractive valuation. What's in the News BEAM-101 for sickle cell disease received FDA RMAT and orphan drug designations; updated Phase 1/2 BEACON data show strong, durable increases in fetal hemoglobin, with sustained safety and efficacy for 17 treated patients.
Shared on24 Apr 25Fair value Increased 10%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 18%
AnalystConsensusTarget has increased future PE multiple from 397.2x to 472.3x.
Shared on02 Apr 25Fair value Decreased 17%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 12%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.